Suchergebnisse

Three alternative scenarios to the much debated present organisation of the Lithuanian State forest sector are examined: (i) the integrated, where all functions are delegated to one central administrative authority – the Danish prototype, (ii) the commercialised, where State forests are managed by a commercial State company – the Irish prototype, and (iii) the minimalistic, where only negligible forest areas of special importance remain in State ownership – the Swedish prototype. The scenarios are assessed according to six imperatives: (i) sort out the ambiguity of the present structure, (ii) increase the profitability, (iii) reduce the level of public spending, (iv) accommodate changes in ownership structure, (v) rely on a holistic approach, and (vi) comply with the national forest policy. If adopted, any of the scenarios would most likely improve the various elements of State forestry, although in substantially different ways. Politicians will take the final decision that may be supported by the findings of this study.

The costs to electric utility customers from short-term, limited geographic-scale power disruptions have been studied for many years. However, there is increasing interest among regulators, policy-makers, and utilities in developing and implementing methods for analyzing interruptions that are of longer duration (days, weeks, or longer) and of a larger geographic scope (entire metropolitan areas or regions which may extend across multiple service territories). A 2017 report from the U.S. National Academies of Sciences, Engineering, and Medicine indicated the importance of "develop[ing] comprehensive studies to assess the value to customers of improved reliability and resilience…during large-area, long-duration blackouts." As a contribution toward fulfilling this recommendation, the U.S. Department of Energy's (DOE) Office of Electricity's Transmission Permitting and Technical Assistance Division, in partnership with Lawrence Berkeley National Laboratory (LBNL), convened a workshop to identify research needs and discuss potential avenues for methodological advances in the economics of widespread, long-duration power interruptions. The workshop was organized around six key themes in the economics of widespread, long-duration interruptions. LBNL conducted a competitive solicitation for white papers on these themes, and the authors selected were leading experts in academia, industry, and the non-profit sector. They were tasked with assessing the state of knowledge on particular topics, and identifying research needs and promising directions to expand it. These topics included definitions of resilience and reliability; regional economic modeling approaches; uncertainty quantification; data challenges and opportunities; contingent valuation survey techniques; and reduced-form analytical tools for assessing the impacts of power interruptions of this scale. The authors of the six white papers presented their findings at the workshop, titled "Frontiers in the Economics of Widespread, Long-Duration Power Interruptions," and held in Washington, D.C., on March 6, 2018. Each paper was the subject of its own session, with the presentations followed by comments by assigned discussants, and in turn a general discussion of the papers, their findings, and the issues they raised. In addition to the authors, discussants, and LBNL and DOE staff, the workshop participants comprised government, industry, and academic thought leaders from across the country.

The costs to electric utility customers from short-term, limited geographic-scale power disruptions have been studied for many years. However, there is increasing interest among regulators, policy-makers, and utilities in developing and implementing methods for analyzing interruptions that are of longer duration (days, weeks, or longer) and of a larger geographic scope (entire metropolitan areas or regions which may extend across multiple service territories). A 2017 report from the U.S. National Academies of Sciences, Engineering, and Medicine indicated the importance of "develop[ing] comprehensive studies to assess the value to customers of improved reliability and resilience…during large-area, long-duration blackouts." As a contribution toward fulfilling this recommendation, the U.S. Department of Energy's (DOE) Office of Electricity's Transmission Permitting and Technical Assistance Division, in partnership with Lawrence Berkeley National Laboratory (LBNL), convened a workshop to identify research needs and discuss potential avenues for methodological advances in the economics of widespread, long-duration power interruptions. The workshop was organized around six key themes in the economics of widespread, long-duration interruptions. LBNL conducted a competitive solicitation for white papers on these themes, and the authors selected were leading experts in academia, industry, and the non-profit sector. They were tasked with assessing the state of knowledge on particular topics, and identifying research needs and promising directions to expand it. These topics included definitions of resilience and reliability; regional economic modeling approaches; uncertainty quantification; data challenges and opportunities; contingent valuation survey techniques; and reduced-form analytical tools for assessing the impacts of power interruptions of this scale. The authors of the six white papers presented their findings at the workshop, titled "Frontiers in the Economics of Widespread, Long-Duration Power Interruptions," and held in Washington, D.C., on March 6, 2018. Each paper was the subject of its own session, with the presentations followed by comments by assigned discussants, and in turn a general discussion of the papers, their findings, and the issues they raised. In addition to the authors, discussants, and LBNL and DOE staff, the workshop participants comprised government, industry, and academic thought leaders from across the country.

U.S. Department of Energy ; U.S. National Science Foundation ; Ministry of Science and Education of Spain ; Science and Technology Facilities Council of the United Kingdom ; Higher Education Funding Council for England ; National Center for Supercomputing Applications at the University of Illinois at Urbana-Champaign ; Kavli Institute of Cosmological Physics at the University of Chicago ; Center for Cosmology and Astro-Particle Physics at the Ohio State University ; Mitchell Institute for Fundamental Physics and Astronomy at Texas AM University ; Financiadora de Estudos e Projetos ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Ministerio da Ciencia, Tecnologia e Inovacao ; Deutsche Forschungsgemeinschaft ; Argonne National Laboratory ; University of California at Santa Cruz ; University of Cambridge ; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas-Madrid ; University of Chicago ; University College London ; DES-Brazil Consortium ; University of Edinburgh ; Eidgenossische Technische Hochschule (ETH) Zurich ; Fermi National Accelerator Laboratory ; University of Illinois at Urbana-Champaign ; Institut de Ciencies de l'Espai (IEEC/CSIC) ; Institut de Fisica d'Altes Energies, Lawrence Berkeley National Laboratory ; Ludwig-Maximilians Universitat Munchen ; associated Excellence Cluster Universe ; University of Michigan ; National Optical Astronomy Observatory ; University of Nottingham ; Ohio State University ; University of Pennsylvania ; University of Portsmouth ; SLAC National Accelerator Laboratory, Stanford University ; University of Sussex ; Texas AM University ; National Science Foundation ; MINECO ; Centro de Excelencia Severo Ochoa ; European Research Council under the European Union ; ERC ; NSF Physics Frontier Center ; Kavli Foundation ; Gordon and Betty Moore Foundation ; European Research Council ; CNES ; Royal Society of New Zealand Rutherford Foundation Trust ; Cambridge Commonwealth Trust ; University of Melbourne ; DOE ; ICREA ; Science and Technology Facilities Council ; National Science Foundation: AST-1138766 ; National Science Foundation: PLR-1248097 ; MINECO: AYA2012-39559 ; MINECO: ESP2013-48274 ; MINECO: FPA2013-47986 ; Centro de Excelencia Severo Ochoa: SEV-2012-0234 ; ERC: 240672 ; ERC: 291329 ; ERC: 306478 ; NSF Physics Frontier Center: PHY-0114422 ; Gordon and Betty Moore Foundation: 947 ; European Research Council: FP7/291329 ; DOE: DE-AC02-98CH10886 ; Science and Technology Facilities Council: ST/K00090X/1 ; Science and Technology Facilities Council: ST/N000668/1 ; Science and Technology Facilities Council: ST/L000768/1 ; Science and Technology Facilities Council: ST/M001334/1 ; We measure the cross-correlation between weak lensing of galaxy images and of the cosmic microwave background (CMB). The effects of gravitational lensing on different sources will be correlated if the lensing is caused by the same mass fluctuations. We use galaxy shape measurements from 139 deg(2) of the Dark Energy Survey (DES) Science Verification data and overlapping CMB lensing from the South Pole Telescope (SPT) and Planck. The DES source galaxies have a median redshift of z(med) similar to 0.7, while the CMB lensing kernel is broad and peaks at z similar to 2. The resulting cross-correlation is maximally sensitive to mass fluctuations at z similar to 0.44. Assuming the Planck 2015 best-fitting cosmology, the amplitude of the DESxSPT cross-power is found to be A(SPT) = 0.88 +/- 0.30 and that from DESxPlanck to be A(Planck) = 0.86 +/- 0.39, where A = 1 corresponds to the theoretical prediction. These are consistent with the expected signal and correspond to significances of 2.9 sigma and 2.2 sigma, respectively. We demonstrate that our results are robust to a number of important systematic effects including the shear measurement method, estimator choice, photo-z uncertainty and CMB lensing systematics. We calculate a value of A = 1.08 +/- 0.36 for DESxSPT when we correct the observations with a simple intrinsic alignment model. With three measurements of this cross-correlation now existing in the literature, there is not yet reliable evidence for any deviation from the expected LCDM level of cross-correlation. We provide forecasts for the expected signal-to-noise ratio of the combination of the five-year DES survey and SPT-3G.

Funding for this study was provided by the Aase and Ejner Danielsens Foundation; Academy of Finland (41071, 77299, 102318, 110413, 117787, 121584, 123885, 124243, 124282, 126925, 129378, 134309, 286284); Accare Center for Child and Adolescent Psychiatry; Action on Hearing Loss (G51); Agence Nationale de la 359 Recherche; Agency for Health Care Policy Research (HS06516); ALF/LUA research grant in Gothenburg; ALFEDIAM; ALK-Abello´ A/S; Althingi; American Heart Association (13POST16500011); Amgen; Andrea and Charles Bronfman Philanthropies; Ardix Medical; Arthritis Research UK; Association Diabe`te Risque Vasculaire; Australian National Health and Medical Research Council (241944, 339462, 389875, 389891, 389892, 389927, 389938, 442915, 442981, 496739, 552485, 552498); Avera Institute; Bayer Diagnostics; Becton Dickinson; BHF (RG/14/5/30893); Boston Obesity Nutrition Research Center (DK46200), Bristol-Myers Squibb; British Heart Foundation (RG/10/12/ 28456, RG2008/08, RG2008/014, SP/04/002); Medical Research Council of Canada; Canadian Institutes for Health Research (FRCN-CCT-83028); Cancer Research UK; Cardionics; Cavadis B.V., Center for Medical Systems Biology; Center of Excellence in Genomics; CFI; CIHR; City of Kuopio; CNAMTS; Cohortes Sante´ TGIR; Contrat de Projets E´tat-Re´gion; Croatian Science Foundation (8875); Danish Agency for Science, Technology and Innovation; Danish Council for Independent Research (DFF-1333- 00124, DFF-1331-00730B); County Council of Dalarna; Dalarna University; Danish Council for Strategic Research; Danish Diabetes Academy; Danish Medical Research Council; Department of Health, UK; Development Fund from the University of Tartu (SP1GVARENG); Diabetes Hilfs- und Forschungsfonds Deutschland; Diabetes UK; Diabetes Research and Wellness Foundation Fellowship; Donald W. Reynolds Foundation; Dr Robert Pfleger-Stiftung; Dutch Brain Foundation; Dutch Diabetes Research Foundation; Dutch Inter University Cardiology Institute; Dutch Kidney Foundation (E033); Dutch Ministry of Justice; the DynaHEALTH action No. 633595, Economic Structure Enhancing Fund of the Dutch Government; Else Kro¨ner-Fresenius-Stiftung (2012_A147, P48/08//A11/08); Emil Aaltonen Foundation; Erasmus University Medical Center Rotterdam; Erasmus MC and Erasmus University Rotterdam; the Municipality of Rotterdam; Estonian Government (IUT20-60, IUT24-6); Estonian Research Roadmap through the Estonian Ministry of Education and Research (3.2.0304.11-0312); European Research Council (ERC Starting Grant and 323195:SZ-245 50371-GLUCOSEGENESFP7-IDEAS-ERC); European Regional Development Fund; European Science Foundation (EU/QLRT-2001-01254); European Commission (018947, 018996, 201668, 223004, 230374, 279143, 284167, 305739, BBMRI-LPC-313010, HEALTH-2011.2.4.2-2-EUMASCARA, HEALTH-2011-278913, HEALTH-2011-294713-EPLORE, HEALTH-F2- 2008-201865-GEFOS, HEALTH-F2-2013-601456, HEALTH-F4-2007-201413, HEALTH-F4-2007-201550-HYPERGENES, HEALTH-F7-305507 HOMAGE, IMI/ 115006, LSHG-CT-2006-018947, LSHG-CT-2006-01947, LSHM-CT-2004-005272, LSHM-CT-2006-037697, LSHM-CT-2007-037273, QLG1-CT-2002-00896, QLG2-CT2002-01254); Faculty of Biology and Medicine of Lausanne; Federal Ministry of Education and Research (01ZZ0103, 01ZZ0403, 01ZZ9603, 03IS2061A, 03ZIK012); Federal State of Mecklenburg-West Pomerania; Fe´de´ration Franc¸aise de Cardiologie; Finnish Cultural Foundation; Finnish Diabetes Association; Finnish Foundation of Cardiovascular Research; Finnish Heart Association; Fondation Leducq; Food Standards Agency; Foundation for Strategic Research; French Ministry of Research; FRSQ; Genetic Association Information Network (GAIN) of the Foundation for the NIH; German Federal Ministry of Education and Research (BMBF, 01ER1206, 01ER1507); GlaxoSmithKline; Greek General Secretary of Research and Technology; Go¨teborg Medical Society; Health and Safety Executive; Healthcare NHS Trust; Healthway; Western Australia; Heart Foundation of Northern Sweden; Helmholtz Zentrum Mu¨nchen—German Research Center for Environmental Health; Hjartavernd; Ingrid Thurings Foundation; INSERM; InterOmics (PB05 MIUR-CNR); INTERREG IV Oberrhein Program (A28); Interuniversity Cardiology Institute of the Netherlands (ICIN, 09.001); Italian Ministry of Health (ICS110.1/RF97.71); Italian Ministry of Economy and Finance (FaReBio di Qualita`); Marianne and Marcus Wallenberg Foundation; the Ministry of Health, Welfare and Sports, the Netherlands; J.D.E. and Catherine T, MacArthur Foundation Research Networks on Successful Midlife Development and Socioeconomic Status and Health; Juho Vainio Foundation; Juvenile Diabetes Research Foundation International; KfH Stiftung Pra¨ventivmedizin e.V.; King's College London; Knut and Alice Wallenberg Foundation; Kuopio University Hospital; Kuopio, Tampere and Turku University Hospital Medical Funds (X51001); La Fondation de France; Leenaards Foundation; Lilly; LMUinnovativ; Lundberg Foundation; Magnus Bergvall Foundation; MDEIE; Medical Research Council UK (G0000934, G0601966, G0700931, MC_U106179471, MC_UU_12019/1); MEKOS Laboratories; Merck Sante´; Ministry for Health, Welfare and Sports, The Netherlands; Ministry of Cultural Affairs of Mecklenburg-West Pomerania; Ministry of Economic Affairs, The Netherlands; Ministry of Education and Culture of Finland (627;2004-2011); Ministry of Education, Culture and Science, The Netherlands; Ministry of Science, Education and Sport in the Republic of Croatia (108-1080315-0302); MRC centre for Causal Analyses in Translational Epidemiology; MRC Human Genetics Unit; MRC-GlaxoSmithKline pilot programme (G0701863); MSD Stipend Diabetes; National Institute for Health Research; Netherlands Brain Foundation (F2013(1)-28); Netherlands CardioVascular Research Initiative (CVON2011-19); Netherlands Genomics Initiative (050-060-810); Netherlands Heart Foundation (2001 D 032, NHS2010B280); Netherlands Organization for Scientific Research (NWO) and Netherlands Organisation for Health Research and Development (ZonMW) (56-464- 14192, 60-60600-97-118, 100-001-004, 261-98-710, 400-05-717, 480-04-004, 480-05-003, 481-08-013, 904-61-090, 904-61-193, 911-11-025, 985-10-002, Addiction-31160008, BBMRI–NL 184.021.007, GB-MaGW 452-04-314, GB-MaGW 452-06-004, GB-MaGW 480-01-006, GB-MaGW 480-07-001, GB-MW 940-38-011, Middelgroot-911-09-032, NBIC/BioAssist/RK 2008.024, Spinozapremie 175.010.2003.005, 175.010.2007.006); NATURE COMMUNICATIONS | DOI:10.1038/ncomms14977 ARTICLE NATURE COMMUNICATIONS | 8:14977 | DOI:10.1038/ncomms14977 | www.nature.com/naturecommunications 13 Neuroscience Campus Amsterdam; NHS Foundation Trust; National Institutes of Health (1RC2MH089951, 1Z01HG000024, 24152, 263MD9164, 263MD821336, 2R01LM010098, 32100-2, 32122, 32108, 5K99HL130580-02, AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, AG13196, CA047988, DA12854, DK56350, DK063491, DK078150, DK091718, DK100383, DK078616, ES10126, HG004790, HHSN268200625226C, HHSN268200800007C, HHSN268201200036C, HHSN268201500001I, HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C, HL043851, HL45670, HL080467, HL085144, HL087660, HL054457, HL119443, HL118305, HL071981, HL034594, HL126024, HL130114, KL2TR001109, MH66206, MH081802, N01AG12100, N01HC55015, N01HC55016, N01C55018, N01HC55019, N01HC55020, N01HC55021, N01HC55022, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC95159, N01HC95160, N01HC95161, N01HC95162, N01HC95163, N01HC95164, N01HC95165, N01HC95166, N01HC95167, N01HC95168, N01HC95169, N01HG65403, N01WH22110, N02HL6-4278, N01-HC-25195, P01CA33619, R01HD057194, R01HD057194, R01AG023629, R01CA63, R01D004215701A, R01DK075787, R01DK062370, R01DK072193, R01DK075787, R01DK089256, R01HL53353, R01HL59367, R01HL086694, R01HL087641, R01HL087652, R01HL103612, R01HL105756, R01HL117078, R01HL120393, R03 AG046389, R37CA54281, RC2AG036495, RC4AG039029, RPPG040710371, RR20649, TW008288, TW05596, U01AG009740, U01CA98758, U01CA136792, U01DK062418, U01HG004402, U01HG004802, U01HG007376, U01HL080295, UL1RR025005, UL1TR000040, UL1TR000124, UL1TR001079, 2T32HL007055-36, T32GM074905, HG002651, HL084729, N01-HC25195, UM1CA182913); NIH, National Institute on Aging (Intramural funding, NO1-AG-1-2109); Northern Netherlands Collaboration of Provinces; Novartis Pharma; Novo Nordisk; Novo Nordisk Foundation; Nutricia Research Foundation (2016-T1); ONIVINS; Parnassia Bavo group; Pierre Fabre; Province of Groningen; Pa¨ivikki and Sakari Sohlberg Foundation; Påhlssons Foundation; Paavo Nurmi Foundation; Radboud Medical Center Nijmegen; Research Centre for Prevention and Health, the Capital Region of Denmark; the Research Institute for Diseases in the Elderly; Research into Ageing; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center; Roche; Royal Society; Russian Foundation for Basic Research (NWO-RFBR 047.017.043); Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06); Sanofi-Aventis; Scottish Government Health Directorates, Chief Scientist Office (CZD/16/6); Siemens Healthcare; Social Insurance Institution of Finland (4/26/2010); Social Ministry of the Federal State of Mecklenburg-West Pomerania; Socie´te´ Francophone du 358 Diabe`te; State of Bavaria; Stiftelsen fo¨r Gamla Tja¨narinnor; Stockholm County Council (560183, 592229); Strategic Cardiovascular and Diabetes Programmes of Karolinska Institutet and Stockholm County Council; Stroke Association; Swedish Diabetes Association; Swedish Diabetes Foundation (2013-024); Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation (20120197, 20150711); Swedish Research Council (0593, 8691, 2012-1397, 2012-1727, and 2012-2215); Swedish Society for Medical Research; Swiss Institute of Bioinformatics; Swiss National Science Foundation (3100AO-116323/1, 31003A-143914, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 51RTP0_151019); Tampere Tuberculosis Foundation; Technology Foundation STW (11679); The Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community (G.0880.13, G.0881.13); The Great Wine Estates of the Margaret River Region of Western Australia; Timber Merchant Vilhelm Bangs Foundation; Topcon; Tore Nilsson Foundation; Torsten and Ragnar So¨derberg's Foundation; United States – Israel Binational Science Foundation (Grant 2011036), Umeå University; University Hospital of Regensburg; University of Groningen; University Medical Center Groningen; University of Michigan; University of Utrecht; Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) (b2011036); Velux Foundation; VU University's Institute for Health and Care Research; Va¨stra Go¨taland Foundation; Wellcome Trust (068545, 076113, 079895, 084723, 088869, WT064890, WT086596, WT098017, WT090532, WT098051, 098381); Wissenschaftsoffensive TMO; Yrjo¨ Jahnsson Foundation; and Åke Wiberg Foundation